Results 181 to 190 of about 288,388 (279)

High-risk biochemical recurrence in prostate cancer: identification and early intervention strategies. [PDF]

Front Urol
Abdelaziz AH, Ezz El Din MMA, Hamada E, Abdullah M, Shaker HS, Mourad MS, Osman T, Nowier AM, Gad DS.   +8 more
europepmc   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy. [PDF]

Cancer
Lane BR, Lewicki P, Noyes SL, Labardee C, Meah S, Daignault-Newton S, Hafron J, Morgan TM, Radhakrishnan A, Dess RT, Montie J, Ghani KR, Ginsburg KB, Borza T.   +13 more
europepmc   +1 more source

Sequencing BCR–antigen interactions [PDF]

Nature Methods, 2020
openaire   +2 more sources

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Secondary Chronic Myeloid Leukemia in the Blast Phase With Mixed Phenotype After Radiation Therapy: A Case Report. [PDF]

EJHaem
Aoki M, Maeda T, Kinoshita H, Taji Y, Shintani D, Takahashi N, Ebihara Y.   +6 more
europepmc   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

B Cell Receptor's function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism. [PDF]

PLoS Pathog
Larios R, Hossain MB, Brown R, Jeyachandran AV, Abu AE, Zaiss AK, Ramirez CM, Kamata M, Cole S, Wu TT, Dorshkind K, Arumugaswami V, Morizono K.   +12 more
europepmc   +1 more source